image
Healthcare - Biotechnology - NASDAQ - US
$ 21.13
-1.96 %
$ 2.58 B
Market Cap
13.39
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one CPRX stock under the worst case scenario is HIDDEN Compared to the current market price of 21.1 USD, Catalyst Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one CPRX stock under the base case scenario is HIDDEN Compared to the current market price of 21.1 USD, Catalyst Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one CPRX stock under the best case scenario is HIDDEN Compared to the current market price of 21.1 USD, Catalyst Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CPRX

image
$27.0$27.0$26.0$26.0$25.0$25.0$24.0$24.0$23.0$23.0$22.0$22.0$21.0$21.0$20.0$20.0Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
492 M REVENUE
23.49%
195 M OPERATING INCOME
124.77%
164 M NET INCOME
129.50%
240 M OPERATING CASH FLOW
67.00%
-294 M INVESTING CASH FLOW
-0.00%
141 M FINANCING CASH FLOW
1395.62%
141 M REVENUE
-0.28%
63.4 M OPERATING INCOME
0.83%
56.7 M NET INCOME
1.43%
60 M OPERATING CASH FLOW
-15.29%
0 INVESTING CASH FLOW
100.00%
3.06 M FINANCING CASH FLOW
-30.97%
Balance Sheet Catalyst Pharmaceuticals, Inc.
image
Current Assets 624 M
Cash & Short-Term Investments 518 M
Receivables 65.5 M
Other Current Assets 40.6 M
Non-Current Assets 228 M
Long-Term Investments 21.6 M
PP&E 3.58 M
Other Non-Current Assets 203 M
60.79 %7.69 %4.77 %23.80 %Total Assets$851.4m
Current Liabilities 121 M
Accounts Payable 16.6 M
Short-Term Debt 402 K
Other Current Liabilities 104 M
Non-Current Liabilities 3.1 M
Long-Term Debt 5.57 M
Other Non-Current Liabilities -2.47 M
13.41 %83.76 %4.50 %Total Liabilities$123.8m
EFFICIENCY
Earnings Waterfall Catalyst Pharmaceuticals, Inc.
image
Revenue 492 M
Cost Of Revenue 68.8 M
Gross Profit 423 M
Operating Expenses 228 M
Operating Income 195 M
Other Expenses 31.2 M
Net Income 164 M
500m500m450m450m400m400m350m350m300m300m250m250m200m200m150m150m100m100m50m50m00492m(69m)423m(228m)195m(31m)164mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
86.00% GROSS MARGIN
86.00%
39.68% OPERATING MARGIN
39.68%
33.33% NET MARGIN
33.33%
22.52% ROE
22.52%
19.25% ROA
19.25%
20.22% ROIC
20.22%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Catalyst Pharmaceuticals, Inc.
image
250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 164 M
Depreciation & Amortization 37.8 M
Capital Expenditures -556 K
Stock-Based Compensation 22.3 M
Change in Working Capital 30.9 M
Others 62.3 M
Free Cash Flow 239 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Catalyst Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for CPRX of $31.7 , with forecasts ranging from a low of $28 to a high of $35 .
CPRX Lowest Price Target Wall Street Target
28 USD 32.51%
CPRX Average Price Target Wall Street Target
31.7 USD 49.87%
CPRX Highest Price Target Wall Street Target
35 USD 65.64%
Price
Max Price Target
Min Price Target
Average Price Target
363634343232303028282626242422222020181816161414Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Catalyst Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
12.8 M USD 4
3-6 MONTHS
7.04 M USD 3
6-9 MONTHS
21.1 M USD 5
9-12 MONTHS
5.82 M USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 1 week ago
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 1 week ago
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio. zacks.com - 1 week ago
CPRX or STVN: Which Is the Better Value Stock Right Now? Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck right now? zacks.com - 2 weeks ago
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com - 3 weeks ago
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 3 weeks ago
Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 4 weeks ago
Catalyst (CPRX) Loses 12.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Catalyst (CPRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. zacks.com - 1 month ago
CPRX vs. NBIX: Which Stock Is the Better Value Option? Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX). But which of these two stocks offers value investors a better bang for their buck right now? zacks.com - 1 month ago
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com - 1 month ago
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 1 month ago
4 Stocks With Solid Net Profit Margins to Boost Portfolio Returns Here we present four stocks, GLDD, TILE, CPRX and STRL, with solid net profit margins that can contribute to making a strong portfolio. zacks.com - 1 month ago
8. Profile Summary

Catalyst Pharmaceuticals, Inc. CPRX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 2.58 B
Dividend Yield 0.00%
Description Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Contact 355 Alhambra Circle, Coral Gables, FL, 33134 https://www.catalystpharma.com
IPO Date Nov. 8, 2006
Employees 181
Officers Dr. Preethi Sundaram Ph.D. Chief Strategy Officer Dr. Stanley Iyadurai M.D., Ph.D. Senior Vice President of Medical Affairs & Drug Discovery Mr. Gregg Russo Chief Human Resources Officer Dr. Steven R. Miller Ph.D. Executive Vice President, Chief Operating Officer & Chief Scientific Officer Mr. Jeffrey Del Carmen Executive Vice President & Chief Commercial Officer Mr. Michael W. Kalb CPA Executive Vice President, Treasurer & Chief Financial Officer Mr. Brian Elsbernd J.D. Chief Compliance Officer & Chief Legal Officer Dr. Gary Ingenito M.D., Ph.D. Chief Medical & Regulatory Officer Mr. Richard John Daly M.B.A. President, Chief Executive Officer & Director Ms. Mary Coleman Vice President & Head of Investor Relations